Genefirst Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 16
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $1.85M
Latest Deal Amount
  • Investors
  • 4

Genefirst General Information

Description

Developer of molecular diagnostics kits and devices intended to provide simple, reliable, and effective molecular solutions to aid the accurate diagnosis of diseases. The company's devices are robust easy-to-use, sensitive, and affordable molecular diagnostics technologies and products to researchers, clinicians, and drug companies enabling accurate diagnosis and the delivery of safe and effective medicines.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Medical Supplies
Primary Office
  • Culham Science Centre
  • Building E5, Oxfordshire
  • Abingdon OX14 3DB
  • England, United Kingdom
+44 01865 000000

Genefirst Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Genefirst Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Grant 01-Aug-2020 $1.85M 00.00 Completed Generating Revenue
9. Later Stage VC 19-Mar-2020 00.000 00.00 000.00 Completed Generating Revenue
8. Grant 01-Mar-2018 00000 00.000 Completed Generating Revenue
7. Grant 01-Feb-2018 00000 00.000 Completed Generating Revenue
6. Grant 28-Nov-2017 00.000 00.000 Completed Generating Revenue
5. Grant 01-May-2017 00000 00.000 Completed Generating Revenue
4. Grant 01-Jan-2017 000.00 00.000 Completed Generating Revenue
3. Later Stage VC 07-Jan-2015 00.000 00.000 00.00 Completed Generating Revenue
2. Grant 01-Aug-2014 $42.6K Completed Generating Revenue
1. Corporate 01-Jan-2014 Completed Generating Revenue
To view Genefirst’s complete valuation and funding history, request access »

Genefirst Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference 000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A Preferred 00,000 00.000000 00.00 00.00 00 00.00 0.000
Series A Preferred 587,500 $0.000127 $4.56 $4.56 1x $4.56 28.2%
Ordinary 49,380 $0.000127 $3.1 $3.1 1x $3.1 2.37%
To view Genefirst’s complete cap table history, request access »

Genefirst Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of molecular diagnostics kits and devices intended to provide simple, reliable, and effective molecular soluti
Diagnostic Equipment
Abingdon, United Kingdom
16 As of 2021
00.00
0000000000 00.00

000000 0

iquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum
0000000000 000000000
Pleasanton, CA
00 As of 0000
000000000000

0000000

mod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerci
0000000000 000000000
Rehovot, Israel
00 As of 0000
000.00
0000 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Genefirst Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vortex Biosciences Venture Capital-Backed Pleasanton, CA 00 000000000000
0000000 Venture Capital-Backed Rehovot, Israel 00 000.00 00000000000 000.00
You’re viewing 2 of 2 competitors. Get the full list »

Genefirst Patents

Genefirst Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3060018-A1 Methods, compositions, and kits for preparing nucleic acid libraries Pending 17-Apr-2017 0000000000
AU-2018254190-A1 Methods, compositions, and kits for preparing nucleic acid libraries Pending 17-Apr-2017 0000000000
JP-2020512845-A Methods, compositions, and kits for preparing nucleic acid libraries Pending 17-Apr-2017 0000000000
EP-3612642-A1 Methods, compositions, and kits for preparing nucleic acid libraries Pending 17-Apr-2017 0000000000
US-20200115736-A1 Methods, compositions, and kits for preparing nucleic acid libraries Pending 17-Apr-2017 C12Q1/6806
To view Genefirst’s complete patent history, request access »

Genefirst Executive Team (3)

Name Title Board Seat Contact Info
Guoliang Fu Founder & Chief Executive Officer
Andrew Wood Chief Financial Officer
Winnie Wu Chief Operating Officer
To view Genefirst’s complete executive team members history, request access »

Genefirst Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genefirst Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institute for Health Research Government 000 0000 000000 0
Horizon 2020 Government Minority 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
Fosun Pharma Corporation Minority 000 0000 000000 0
To view Genefirst’s complete investors history, request access »